Jay M. Moyes
CIK: 0001191062
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (9 total)
- Jul 6, 2026BCDA
BioCardia, Inc.
Award(A)DirectStock Option (right to buy)
8K shares- - Jun 12, 2026PBYI
PUMA BIOTECHNOLOGY, INC.
Sale(S)Direct22K shares at avg. $7.22$159K - Jun 11, 2026PBYI
PUMA BIOTECHNOLOGY, INC.
Award(A)Direct27K shares- - Feb 23, 2026SINT
Sintx Technologies, Inc.
Purchase(P)Direct1K shares at avg. $2.91$3K - Dec 8, 2025BCDA
BioCardia, Inc.
Award(A)DirectStock Option (right to buy)
12K shares- - Aug 26, 2025SINT
Sintx Technologies, Inc.
Purchase(P)Direct3K shares at avg. $3.59$11K - Jun 13, 2025PBYI
PUMA BIOTECHNOLOGY, INC.
Sale(S)Direct22K shares at avg. $3.40$75K - Jun 11, 2025PBYI
PUMA BIOTECHNOLOGY, INC.
Award(A)Direct27K shares- - Oct 11, 2024BCDA
BioCardia, Inc.
Award(A)DirectStock Option (right to buy)
829 shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jul 6, 2026 |  BCDA BioCardia, Inc. | Award(A) Stock Option (right to buy) | 8,000 | - | - | Direct |
| Jun 12, 2026 |  PBYI PUMA BIOTECHNOLOGY, INC. | Sale(S) | 22,000 | $7.22 | $158,796 | Direct |
| Jun 11, 2026 | PBYI PUMA BIOTECHNOLOGY, INC. | Award(A) | 27,000 | - | $0 | Direct |
| Feb 23, 2026 |  SINT Sintx Technologies, Inc. | Purchase(P) | 1,000 | $2.91 | $2,910 | Direct |
| Dec 8, 2025 | BCDA BioCardia, Inc. | Award(A) Stock Option (right to buy) | 12,000 | - | - | Direct |
| Aug 26, 2025 | SINT Sintx Technologies, Inc. | Purchase(P) | 3,000 | $3.59 | $10,756 | Direct |
| Jun 13, 2025 | PBYI PUMA BIOTECHNOLOGY, INC. | Sale(S) | 22,000 | $3.40 | $74,800 | Direct |
| Jun 11, 2025 | PBYI PUMA BIOTECHNOLOGY, INC. | Award(A) | 27,000 | - | - | Direct |
| Oct 11, 2024 | BCDA BioCardia, Inc. | Award(A) Stock Option (right to buy) | 829 | - | - | Direct |
1-9 of 9 transactions
About MOYES JAY M
MOYES JAY M (SEC CIK 0001191062) files insider reports with the SEC as Director of BioCardia, Inc. (BCDA), Director of PUMA BIOTECHNOLOGY, INC. (PBYI) and Director of Sintx Technologies, Inc. (SINT).
Signal8 holds 8 ownership filings by MOYES JAY M, all Form 4s, filed between Oct 16, 2024 and Jul 7, 2026. Those filings report 9 transactions, from Oct 11, 2024 to Jul 6, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on MOYES JAY M's filings is in SUNNYVALE, CA.
Recent filings by MOYES JAY M
- Jul 6, 2026: Grant or award of BCDA derivative securities (Form 4, code A).
- Jun 12, 2026: Open-market sale of PBYI shares (Form 4, code S).
- Jun 11, 2026: Grant or award of PBYI shares (Form 4, code A).
- Feb 23, 2026: Open-market purchase of SINT shares (Form 4, code P).
- Dec 8, 2025: Grant or award of BCDA derivative securities (Form 4, code A).
Other insiders filing for BioCardia, Inc. (BCDA)
- Altman Peter, President and CEO
- STERTZER SIMON H, Director
- Slosman Marvin, Director
- McClung David, Chief Financial Officer
- GILLIS EDWARD M, Senior Vice President, Devices
- Blank Andrew Scott, Director